Headache (frequency) · patients with tension‐type headache
1 finding from 1 review
Headache intensity (mean score) · patients with tension‐type headache
1 finding from 1 review
Intervention not reported
Number of patients with at least 30% pain reduction · Patients with fibromyalgia
It is very uncertain whether the intervention changes number of patients with at least 30% pain reduction (very low certainty).
1 finding from 1 review
Intervention not reported
Number of patients with a clinically important global improvement · Patients with fibromyalgia
It is very uncertain whether the intervention changes number of patients with a clinically important global improvement (very low certainty).
1 finding from 1 review
Intervention not reported
Fatigue (lower scores mean less fatigue) · Patients with fibromyalgia
1 finding from 1 review
Intervention not reported
Sleep problems (lower scores mean less sleep problems) · Patients with fibromyalgia
1 finding from 1 review
Intervention not reported
Depression (lower scores mean less depression) · Patients with fibromyalgia
1 finding from 1 review
Intervention not reported
Discontinuation due to adverse events · Patients with fibromyalgia
It is very uncertain whether the intervention changes discontinuation due to adverse events (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events · Patients with fibromyalgia
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Exacerbation of IBD · IBD patients
Etoricoxib showed no clear difference in exacerbation of IBD compared with placebo (low certainty).
1 finding from 1 review
Exacerbation of ulcerative colitis · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in exacerbation of ulcerative colitis compared with placebo (low certainty).
1 finding from 1 review
GI adverse events · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Luteal administration · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Continuous administration · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Moderate dose SSRI versus placebo Luteal administration2 · women with premenstrual syndrome
1 finding from 1 review
Intervention not reported
Low dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
The intervention probably leads to higher low dose SSRI versus placebo Luteal or continuous administration (moderate certainty).
1 finding from 1 review
Intervention not reported
Mod dose SSRI versus placebo Luteal or continuous administration · women with premenstrual syndrome
The intervention probably leads to higher mod dose SSRI versus placebo Luteal or continuous administration (moderate certainty).
1 finding from 1 review
Intervention not reported
High dose SSRIs versus placebo Continuous administration · women with premenstrual syndrome
The intervention probably leads to higher high dose SSRIs versus placebo Continuous administration (moderate certainty).
1 finding from 1 review
Percent change from baseline in leiomyoma size · patients with uterine leiomyomas
1 finding from 1 review